23 May 2013
Keywords: pozen, deal, gsk, new, migraine, drug, glaxosmithkline
Article | 23 June 2003
GlaxoSmithKline, Europe's leading drugmaker, has signed a licensing deal with USA-based drug development concern Pozen that could be worth
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
23 June 2003
16 June 2003
22 May 2013
© 2013 thepharmaletter.com